Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for MARKER THERAPEUTICS, INC. (MRKR : NSDQ)
 
 • Company Description   
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment and eradication of cancer, including metastatic cancer. The company's product pipeline consists of MultiTAA T Cell Therapy, TPIV200 and TPIV100/110 which are in clinical stage. Marker Therapeutics Inc., formerly known as TapImmune Inc., is based in FL, United States.

Number of Employees: 5

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.39 Daily Weekly Monthly
20 Day Moving Average: 343,400 shares
Shares Outstanding: 16.67 (millions)
Market Capitalization: $23.18 (millions)
Beta: 1.35
52 Week High: $5.95
52 Week Low: $0.81
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 45.58% 42.50%
12 Week 54.44% 51.66%
Year To Date -55.31% -61.44%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2450 Holcombe Blvd Suite BCM-A
-
Houston,TX 77021
USA		 ph: 713-400-6400
fax: -		 investor.relations@markertherapeutics.com http://www.markertherapeutics.com
 
 • General Corporate Information   
Officers
Juan Vera - President; Chief Executive Officer and Treasurer
N. David Eansor - Chairman
Katharine Knobil - Director
Steve Elms - Director
John Wilson - Director

Peer Information
MARKER THERAPEUTICS, INC. (GSAC)
MARKER THERAPEUTICS, INC. (CASI)
MARKER THERAPEUTICS, INC. (ALCD.)
MARKER THERAPEUTICS, INC. (OMNN)
MARKER THERAPEUTICS, INC. (CGPI.)
MARKER THERAPEUTICS, INC. (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 57055L206
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 03/30/26
Share - Related Items
Shares Outstanding: 16.67
Most Recent Split Date: 1.00 (0.10:1)
Beta: 1.35
Market Capitalization: $23.18 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.20 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.95 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 03/30/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.98
Price/Cash Flow: -
Price / Sales: 4.94
EPS Growth
vs. Year Ago Period: 53.85%
vs. Previous Quarter: 58.62%
Sales Growth
vs. Year Ago Period: -35.98%
vs. Previous Quarter: 43.21%
ROE
09/30/25 - -92.35
06/30/25 - -114.59
03/31/25 - -101.87
ROA
09/30/25 - -75.73
06/30/25 - -90.31
03/31/25 - -83.02
Current Ratio
09/30/25 - 6.50
06/30/25 - 3.45
03/31/25 - 6.79
Quick Ratio
09/30/25 - 6.50
06/30/25 - 3.45
03/31/25 - 6.79
Operating Margin
09/30/25 - -304.54
06/30/25 - -271.10
03/31/25 - -224.46
Net Margin
09/30/25 - -304.56
06/30/25 - -271.12
03/31/25 - -224.46
Pre-Tax Margin
09/30/25 - -303.47
06/30/25 - -270.17
03/31/25 - -223.56
Book Value
09/30/25 - 1.42
06/30/25 - 0.93
03/31/25 - 1.28
Inventory Turnover
09/30/25 - -
06/30/25 - -
03/31/25 - -
Debt-to-Equity
09/30/25 - 0.00
06/30/25 - 0.00
03/31/25 - 0.00
Debt-to-Capital
09/30/25 - 0.00
06/30/25 - 0.00
03/31/25 - 0.00
 

Powered by Zacks Investment Research ©